Structure-Activity Relationships (Sar) and Structure-Metabolism Relationships (Smr) Affecting the Teratogenicity of Carboxylic Acids

References

• Di Carlo F. J., Bickart P., Auer C. M. Structure-metabolism relationships (SMR) for the prediction of health hazards by the Environmental Protection Agency. I. Background for the practice of predictive toxicology. Drug Metab. Rev. 1986; 17: 119–132
   Google Scholar
• Di Carlo F. J., Bickart P., Auer C. M. Structure-metabolism relationships (SMR) for the prediction of health hazards by the Environmental Protection Agency. II. Application to teratogenicity and other toxic effects caused by aliphatic acids. Drug Metab. Rev. 1986; 17: 187–220
   PubMed Web of Science ®Google Scholar
• Gunstone F. D. Comprehensive Organic Chemistry, D. Barton, W. D. Ollis, E. Haslam. Pergamon Press, Oxford 1979; vol. 5: 587–595
   Google Scholar
• Johnson E. M., Newman L. M., Fu L. -J. Letter to the editor. Toxicol. Appl. Pharmacol 1989; 99: 173–176
   PubMedGoogle Scholar
• Flint O. Letter to the editor. Toxicol. Appl. Pharmacol 1989; 99: 176–180
   Google Scholar
• Freese E. Use of cultured cells in the identification of potential teratogens. Terat., Carcin., Mutagen. 1982; 2: 355–360
   PubMedGoogle Scholar
• Scott W. J., Nau H. Weak acids as human teratogens: Accumulation in the young mammalian embryo. Teratology 1985; 31: 25A
   Google Scholar
• Beckman D. A., Brent R. L. Mechanisms of teratogenesis. Ann. Rev. Pharmacol. Toxicol 1984; 24: 483–500
   PubMed Web of Science ®Google Scholar
• Brent R. L. Environmental factors: Miscellaneous. Prevention of Embryonic, Fetal, and Perinatal Disease, R. L. Brent, M. I. Harris. DHEW Publ. No. (NIH) 76–853, Bethesda, MD 1976; 211–218
   Google Scholar
• Brent R. L. Drugs and pregnancy: Are the insert warnings too dire?. Contemp. OB-Gyn. 1982; 20: 42–49
   Google Scholar
• Wilson J. G. Environmental and Birth Defects. Academic Press, New York 1973
   Google Scholar
• Wilson J. G. Mechanisms of teratogenesis. Am. J. Anat 1973; 136: 129–132
   PubMedGoogle Scholar
• Stephens T. D. Proposed mechanisms of action of thalidomide embryopathy. Teratology 1988; 38: 229–239
   PubMedGoogle Scholar
• Brown L. P., Flint O. P., Orton T. C., Gibson G. G. Chemical teratogenesis: Testing methods and the role of metabolism. Drug Metab. Rev. 1986; 17: 221–260
   PubMed Web of Science ®Google Scholar
• Nau H., Hendrickx A. G. Valproic acid teratogenesis. ISI Atlas of Science: Pharmacology 1987; 52–56
   Google Scholar
• Toraason M., Breitenstein M. J., Smith R. J. Ethylene glycol monomethyl ether (EGME) inhibits rat embryo ornithine decarboxylase (ODC) activity. Drug Chem. Toxicol 1986; 9: 191–203
   PubMed Web of Science ®Google Scholar
• Miller R. R., Hermann E. A., Langvardt P. W., McKenna M. J., Schwetz B. A. Comparative metabolism and disposition of ethylene glycol monomethyl ether and propylene glycol monomethyl ether in male rats. Toxicol. Appl. Pharmacol 1983; 67: 229
   PubMed Web of Science ®Google Scholar
• Miller R. R. Metabolism and disposition of glycol ethers. Drug Metab. Rev. 1987; 18: 1–22
   PubMed Web of Science ®Google Scholar
• Ritter E. J., Scott W. J., Jr., Randall J. L., Ritter J. M. Teratogenicity of dimethoxyethyl phthalate and metabolites methoxyethanol and methoxyacetic acid in the rat. Teratology 1985; 32: 25–31
   PubMedGoogle Scholar
• Mebus C. A., Welsch F. The possible role of one-carbon moieties in 2-methoxyethanol and 2-methoxyacetic acid-induced developmental toxicity. Toxicol. Appl. Pharmacol 1989; 99: 98–109
   PubMed Web of Science ®Google Scholar
• Frisell W. R., MacKenzie C. G. The binding sites of sarcosine oxidase. J. Biol. Chem. 1955; 217: 275–285
   PubMed Web of Science ®Google Scholar
• Porter D. H., Cook R. J., Wagner C. Enzymatic properties of dimethylglycine dehydrogenase and sarcosine dehydrogenase from rat liver. Arch. Biochem. Biophys. 1985; 243: 396–407
   PubMed Web of Science ®Google Scholar
• Willhite C. C. Molecular correlates in retinoid pharmacology and toxicology. Chemistry and Biology of Synthetic Retinoids, M. I. Dawson, W. H. Okamura. CRC Press, Boca Raton, FL 1989
   Google Scholar
• Nau H., private communication
   Google Scholar
• Darmon M., Rocher M., Cavey M. -T., Martin B., Rabilloud T., Delescluse C., Shroot B. Biological activity of retinoids correlates with affinity for nuclear receptors but not for cytosolic binding protein. Skin Pharmacol 1988; 1: 161–175
   PubMedGoogle Scholar
• Hauck R. -S., Nau H. Asymmetric synthesis and enantio selective teratogenicity of 2-n-propyl-4-pentenoic acid (4-en-VPA), an active metabolite of the anticonvulsant drug, valproic acid. Toxicology Letters 1989; 49: 41–8
   PubMed Web of Science ®Google Scholar
• Hauck R. -S., Wegner C., Blumtritt P., Fuhrhop J. -H., Nau H. Asymmetric synthesis and teratogenic activity of (R)- and (S)-2-ethylhexanoic acid, a metabolite of the plasticizer, di-(2-ethylhexyl) phthalate. Life Sciences 1990; 46: 513–518
   PubMed Web of Science ®Google Scholar
• Brown N. A., Farmer P. B., Coakley M. Valproic acid teratogenicity: Demonstration that the biochemical mechanism differs from that of valproate hepatotoxicity. Biochem. Soc. Trans. 1985; 13: 75–77
   PubMed Web of Science ®Google Scholar
• Goulding E. H., Jetten A. M., Abbott B. D., Pratt R. M. Teratogenicity of benzoic acid derivatives of retinoic acid in cultured mouse embryos. Reprod. Teratol 1988; 2: 91–98
   Google Scholar
• Schulz H. Metabolism of 4-pentenoic acid and inhibition of thiolase by metabolites of 4-pentenoic acid. Biochemistry 1983; 22: 1827–1832
   PubMed Web of Science ®Google Scholar
• Stokke O. The degradation of branched chain fatty acid by alterations between a- and P-oxidations. Biochim. Biophys. Acta 1969; 176: 54–59
   PubMed Web of Science ®Google Scholar
• Steinberg D., Herndon J. H., Jr., Uhlendorf W., Mize C. E., Avigan J., Milne G. W. A. Refsum's disease. Nature of the enzyme defect. Science 1967; 156: 1740–1742
   PubMed Web of Science ®Google Scholar
• Steinberg D., Avigan J., Mize C. E., Herndon J. H., Jr., Fales H. M., Milne G. W. A. Metabolic defect in Refsum's disease. Pathol. Eur. 1968; 3: 450–458
   PubMedGoogle Scholar
• Steinberg D. Phytanic acid storage disease. Refsum's syndrome. Metabolic Basis of Inherited Diseases3rd Ed., J. B. Stanburg, J. B. Wyngaarden, D. S. Frederickson. McGraw Hill, New York 1972; 833–853
   Google Scholar
• Granneman G. R., Wang S. I., Machinist J. M., Kesterson J. W. Aspects of the metabolism of valproic acid. Xenobiotica 1984; 14: 375–387
   PubMed Web of Science ®Google Scholar
• Ravindranath V., Burka L. T., Boyd M. R. Isolation and characterization of the reactive metabolites of 2-methylfuran (2-MF) and 3-methylfuran (3-MF). The Pharmacologist 1983; 25: 171
   Google Scholar
• Ravindranath V., Boyd M. R. Metabolic activation of 2-methylfuran by rat microsomal systems. Toxicol. Appl. Pharmacol. 1985; 78: 370–376
   PubMed Web of Science ®Google Scholar
• Creech Kraft J., Lofberg B., Chahoud I., Bochert G., Nau H. Teratogenicity and placental transfer of all-trans-, 13-cis- 4-oxo-all-trans- and 4-oxo-13-cis-retinoic acid after administration of a low oral dose during organogenesis in mice. Toxicol. Appl. Pharmacol. 1989; 100: 162–176
   PubMed Web of Science ®Google Scholar
• Sorensen J. S., Sorensen N. A. Acta Chem. Scand. 1954; 8: 1741–1749
   Google Scholar
• Bernhard K., Yekundi K., Kaempf E. Biological behavior of fatty acids with triple bonds. III. Degradation of tariric acid. Helv. Chim. Acta 1968; 51: 373–376
   PubMed Web of Science ®Google Scholar
• Wagner H., Ritzel G., Bernhard K. Biological behavior of fatty acids with triple bonds. I. Storage and degradation of stearolic acid in rats. Helv. Chim. Acta 1966; 49: 436–440
   Web of Science ®Google Scholar
• Ishida T., Toyota M., Asakawa Y. Terpenoid biotransformation in mammals. V. Metabolism of (+)-citronellal, (±)-7-hydroxycitronellal, citral, (-)-perillaldehyde, (-)-myrtenal, cuminaldehyde, thujone, and (±)-carvone in rabbits. Xenobiotica 1989; 19: 843–855
   PubMed Web of Science ®Google Scholar
• Fenaroli 's Handbook of Flavor Ingredients, T. E. Furia, N. Bellanca. CRC Press, Cleveland, OH 1975
   Google Scholar
• Albert Adrien, private communication
   Google Scholar
• Kuhara T., Matsumoto I., Ohno M. Identification and quantification of octanoyl glucuronide in the urine of children who ingested medium-chain triglycerides. Biomed. Environ. Mass Spectrom. 1986; 13: 595–598
   PubMedGoogle Scholar
• Petkovich M., Brand N. J., Krust A., Chambon P. A human retinoic acid receptor which belongs to the family of nuclear receptors. Nature 1987; 330: 444–450
   PubMed Web of Science ®Google Scholar
• Giguere V., Ong E. S., Segui P., Evans R. M. Identification of a receptor for the morphogen retinoic acid. Nature 1987; 330: 624–629
   PubMed Web of Science ®Google Scholar
• Evans R. M. The steroid and thyroid hormone receptor superfamily. Science 1988; 240: 889–895
   PubMed Web of Science ®Google Scholar
• Poland A., Glover E., Kende A. Stereospecific, high affinity binding of 2,3,7,8-tetrachlorodibenzo-p-dioxin by hepatic cytosol. Evidence that the binding species is receptor for induction of aryl hydrocarbon hydroxylase. J. Biol Chem. 1976; 251: 493–946
   PubMedGoogle Scholar
• Abbott B. D., Birnbaum L. S. Cellular alterations and enhanced induction of cleft palate after coadministration of retinoic acid and TCDD. Toxicol. Appl. Pharmacol. 1989; 99: 287–301
   PubMed Web of Science ®Google Scholar
• Russell D. H. Ornithine decarboxylase: A key regulatory enzyme in normal and neoplastic growth. Drug Metab. Rev. 1985; 16: 1–88
   PubMed Web of Science ®Google Scholar
• Webster's Third New International Dictionary. G.&C. Merriam, Springfield, MA 1971
   Google Scholar
• Di Carlo F. J. Metabolism, pharmacokinetics, and toxicokinetics defined. Drug Metab. Rev. 1981; 13: 1–4
   Web of Science ®Google Scholar
• Nau H., Loscher W. Pharmacologic evaluation of various metabolites and analogs of valproic acid: Teratogenic potencies in mice. Fund. Appl. Toxicol. 1986; 6: 669–676
   PubMedGoogle Scholar
• Kao J., Brown N. A., Schmid B., Goulding E. H., Fabro S. Teratogenicity of valproic acid: In vivo and in vitro investigations. Teratogen. Carcinogen. Mutagen. 1981; 1: 367–382
   Google Scholar
• Suskind R. R., Stemmer K. L., Barkely W. Chronic mouse dermal toxicity study of valeric acid, n-heptanoic acid and n-nonanoic acid, Kettering Laboratory. 1985, 8EHQ-0784–0514C
   Google Scholar
• Brown N. A., Colhoun C. W. Valproic acid teratogenesis. I. In vivo/in vitro comparisons and effects on somite morphogenesis. Teratology 1984; 29: 20A–21A
   Google Scholar
• Brown N. A., Coakely M. E. Valproic acid teratogenesis. II. Actions of related drugs and potential antagonists and the role of coenzyme A. Teratology 1984; 29: 20A
   Google Scholar
• Rawlings S. J., Shuker D. E. G., Webb M., Brown N. A. The teratogenic potential of alkoxy acids in postimplantation rat embryo culture: Structure-activity relationships. Toxicol. Lett. 1985; 28: 49–58
   PubMed Web of Science ®Google Scholar
• Yonemoto J., Brown N. A., Webb M. Effects of dimethoxyethyl phthalate, monomethoxyethyl phthalate, 2-methoxyethanol and methoxyacetic acid on post implantation rat embryos in culture. Toxicol. Lett. 1984; 21: 97–102
   PubMed Web of Science ®Google Scholar
• Nau H., Lewandowski C., Klug S., Neubert D. Pharmacokinetic aspects of drug effects in vitro (II): Placental transfer to the embryo and activity of some carboxylic acids structurally related to valproic acid in whole embryos in culture. Toxicol, in Vitro 1988; 2: 169–174
   PubMed Web of Science ®Google Scholar
• Ritter E. J., Scott W. J., Jr., Randall J. L., Ritter J. M. Teratogenicity of dimethoxyethyl phthalate and metabolites methoxyethanol and methoxyacetic acid in the rat. Teratology 1985; 32: 25–31
   PubMedGoogle Scholar
• Kavlock Robert J., personal communication
   Google Scholar
• Schardein J. L. Chemically Induced Birth Defects. Marcel Dekker, New York 1985; 146, 176, 443–445, 710–714, 733, 740
   Google Scholar
• Lindhout D., Meinardi H. Spina bifida and in-utero exposure to valproate. Lancet 1984; 2: 396
   PubMed Web of Science ®Google Scholar
• Robert E., Kofkvist E., Mauguiere F. Valproate and spina bifida. Lancet 1984; 2: 1392
   PubMed Web of Science ®Google Scholar
• Tein I., MacGregor D. L. Possible valproate teratogenicity. Arch. Neurol. 1985; 43: 291–293
   Google Scholar
• Mast T. J., Cukierski M. A., Nau H., Hendrickx A. G. Predicting the human teratogenic potential of the anticonvulsant, valproic acid, from a non-human primate model. Toxicology
   PubMed Web of Science ®Google Scholar
• Mast T. J., Hendrickx A. G., Nau H. Teratology and pharmacokinetics of valproic acid in the rhesus monkey. Teratology 1985; 29: 47A
   Google Scholar
• Miyagawa A., Koyama K., Hara T., Imamura S., Ohguro T., Hatano H. Toxicity tests with sodium dipropyl acetate, Report. Hofu Factory of Kyowa Fermentation Ind., Ltd. 1971; 448
   Google Scholar
• Whittle B. A. Pre-clinical teratological studies on sodium valproate (Epillim) and other anticonvulsants. Clinical and Pharmacological Aspects of Sodium Valproate (Epillim) in the Treatment of Epilepsy Proc. Symp., N. J. Legg. Tunbridge Wells, NottinghamEngland 1976; 105–111
   Google Scholar
• Petrere J. A., Wise L. D., Anderson J. A., Fitzgerald J. E., de la Iglesia F. A. Teratology study in rabbits whith calcium valproate. Teratology 1984; 29: 50A
   Google Scholar
• Moffa A. M., White J. A., Mackay E. G., Frias J. L. Valproic acid, zinc and open neural tubes in 9-day-old hamster embryos. Teratology 1985; 29: 47A
   Google Scholar
• Ong L. L., Schardein J. L., Petrere J. A., Sakowski R., Jordan H., Humphrey R. R., Fitzgerald J. E., de la Iglesia F. A. Teratogenesis of calcium valproate in rats. Fund. Appl. Toxicol 1983; 3: 121–126
   PubMedGoogle Scholar
• Ritter E. J., Scott W. J., Randall J. L., Ritter J. M. Teratogenicity of di(2-ethylhexyl<)phthalate7 2-ethylhexaneol, 2-ethylhexanoic acid, and valproic acid, and potentiation by caffeine. Teratology 1987; 35: 41–46
   PubMedGoogle Scholar
• Smith K., Thompson G. F., Koster H. O. Sweat in schizophrenic patients: Identification of the odorous substance. Science 1969; 166: 398–399
   PubMed Web of Science ®Google Scholar
• Hauck R. -S., Nau H. Zu den stnikturellen Grundlagen der teratogenen Wirkung des Antiepileptikums Valproinsaure (VPA). Naturwissenschaften 1989; 76: 528–529
   PubMedGoogle Scholar
• Howard W. B., Willhite C. C., Dawson M. I., Sharma R. P. Structure-activity relationships of retinoids in developmental toxicology. III. Contribution of the vitamin A-cyclogeranylidene ring. Toxicol. Appl. Pharmacol. 1988; 95: 122–138
   PubMed Web of Science ®Google Scholar
• Lewandowski C., Klug S., Nau H., Neubert D. Pharmacokinetic aspects of drug effects in vitro: Effects of serum protein binding on concentration and teratogenicity of valproic acid and 2-en-valproic acid in whole embryos in culture. Arch. Toxicol
   Web of Science ®Google Scholar
• Willhite C. C. Structure-activity relationships of retinoids in developmental toxicology. II. Influence of the polyene chain of the vitamin A molecule. Toxicol. Appl. Pharmacol 1986; 83: 563–575
   PubMed Web of Science ®Google Scholar
• Willhite C. C., Dawson M. I., Williams K. J. Structure-activity relationships of retinoids in developmental toxicology. I. Studies on the nature of the polar terminus of the vitamin A molecule. Toxicol. Appl. Pharmacol. 1984; 74: 397–410
   PubMed Web of Science ®Google Scholar
• Howard W. B., Willhite C. C., Sharma R. P. Structure-toxicity relationships of the tetramethylated tetralin and indane analogs of retinoic acid. Teratology 1987; 36: 303–311
   PubMedGoogle Scholar
• Flanagan J. L., Willhite C. C., Ferm V. H. Comparative teratogenic activity of cancer chemopreventive retinoidal benzoic acid congeners (arotinoids). J. Natl. Cane. Inst. 1987; 78: 533–538
   PubMed Web of Science ®Google Scholar